Psychiatrist.comThe Prescriber’s Guide to Oral Ketamine for Patients With Major Depressive Illness: Principles and Practice

🎓 Expert Commentary / Peer Perspective

This educational review provides a detailed framework for the off-label use of orally administered racemic ketamine in major depressive illness, particularly severe depression, suicidal crises, and treatment-resistant depression. Rather than presenting new efficacy data, the article synthesizes clinical trial evidence, safety literature, regulatory developments, and the author’s decade of clinical experience. The review positions oral ketamine as a potentially accessible alternative to intravenous ketamine and intranasal esketamine, especially in resource-limited settings, while acknowledging regulatory, safety, and evidence limitations associated with off-label use.

Clinical Considerations

• Existing evidence supports ketamine’s rapid antidepressant and antisuicidal effects, though most research has focused on intravenous administration and treatment-resistant depression.
• One randomized trial cited in the review found oral ketamine produced similar short-term depression outcomes to intravenous ketamine in treatment-resistant depression, with lower dropout rates and fewer reported adverse effects.
• The article proposes structured protocols for patient evaluation, informed consent, dosing, monitoring, maintenance treatment, and selected domiciliary use.
• Oral ketamine remains an off-label intervention, and recommendations derive largely from existing literature, clinical experience, and limited direct oral-ketamine trial data.
• The review stresses caution in patients with substance-use histories, psychotic disorders, pregnancy considerations, and potential drug-interaction scenarios.
• Long-term safety, optimal maintenance schedules, predictors of response, and comparative effectiveness require further prospective investigation.

Practice Applications

• Consider oral ketamine as an emerging treatment pathway where conventional treatments, ECT access, or approved ketamine formulations are unavailable or impractical.
• Review local regulatory requirements, informed-consent standards, and controlled-substance obligations before adopting oral ketamine protocols.
• Interpret current evidence as supportive but not definitive, particularly for oral formulations and long-term maintenance therapy.
• Monitor patients for dissociative symptoms, cardiovascular effects, substance-use concerns, and treatment durability.
• Discuss oral ketamine within the broader context of established depression treatments, including antidepressants, esketamine, psychotherapy, and ECT.